Thomas Shenk
Princeton University
H-index: 127
North America-United States
Description
Thomas Shenk, With an exceptional h-index of 127 and a recent h-index of 45 (since 2020), a distinguished researcher at Princeton University, specializes in the field of Biological sciences, biomedical sciences, virology.
His recent articles reflect a diverse array of research interests and contributions to the field:
An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity
Paul Berg: Recombinant DNA trailblazer
Sirtuin 4 (SIRT4) lipoamidase activity and uses thereof
An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity
Virology under the microscope—a call for rational discourse
Compositions and Methods for Inhibiting Cancers and Viruses
Method to Produce Virus in Cultured Cells Supplemented With Alpha-Ketoglutarate
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
Professor Information
University | Princeton University |
---|---|
Position | ___ |
Citations(all) | 54274 |
Citations(since 2020) | 7244 |
Cited By | 49748 |
hIndex(all) | 127 |
hIndex(since 2020) | 45 |
i10Index(all) | 290 |
i10Index(since 2020) | 157 |
University Profile Page | Princeton University |
Research & Interests List
Biological sciences
biomedical sciences
virology
Top articles of Thomas Shenk
An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity
296 million people worldwide are predisposed to developing severe end-stage liver diseases due to chronic hepatitis B virus (HBV) infection. HBV forms covalently closed circular DNA (cccDNA) molecules that persist as episomal DNA in the nucleus of infected hepatocytes and drive viral replication. Occasionally, the HBV genome becomes integrated into host chromosomal DNA, a process that is believed to significantly contribute to circulating HBsAg levels and HCC development. Neither cccDNA accumulation nor expression from integrated HBV DNA are directly targeted by current antiviral treatments. In this study, we investigated the antiviral properties of a newly described allosteric modulator, FLS-359, that targets sirtuin 2 (SIRT2), an NAD+-dependent deacylase. Our results demonstrate that SIRT2 modulation by FLS-359 and by other tool compounds inhibits cccDNA synthesis following de novo infection of …
Authors
Liudi Tang,Stacy Remiszewski,Andrew Snedeker,Lillian W Chiang,Thomas Shenk
Journal
Antiviral Research
Published Date
2024/4/18
Paul Berg: Recombinant DNA trailblazer
“I was born in New York on June 30, 1926, and my formative years were spent in a small, gated community named Sea Gate, at the southernmost tip of Brooklyn. By the time I reached junior high school, I had already formed a strong ambition to be a scientist, in part stimulated by my readings about medical scientists:“Arrowsmith” by Sinclair Lewis and “Microbe Hunters” by Paul DeKruif. An inspiring high school “teacher,” Sophie Wolfe, whose job was to supervise the stockroom that supplied the classes in chemistry, physics, and biology, nurtured that ambition. Her love of young people and interest in science led her to start an after-school program of science clubs. Rather than answering questions we asked, she encouraged us to seek solutions for ourselves, which most often turned into mini research projects. Sometimes that involved experiments in the small lab she kept but sometimes it meant going to the library …
Authors
Stephen P Goff,Thomas Shenk
Journal
Proceedings of the National Academy of Sciences
Published Date
2023/11/21
Sirtuin 4 (SIRT4) lipoamidase activity and uses thereof
The present application provides a method of assaying pyruvate dehydrogenase complex (PDHC) activity in a mammalian cell that expresses human sirtuin 4 (SIRT4) comprising measuring a level of a dihydrolipoyllysine acetyltransferase (DLAT) lipoamide peptide comprising the amino acid sequence TDK [lipoyl] AT in the cell. The present application also demonstrates that sirtuin 4 (SIRT4) acts as a cellular lipoamidase that negatively regulates pyruvate dehydrogenase complex (PDHC) activity through hydrolysis of its lipoamide cofactors.
Published Date
2023/8/15
An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity
Most drugs used to treat viral disease target a virus-coded product. They inhibit a single virus or virus family, and the pathogen can readily evolve resistance. Host-targeted antivirals can overcome these limitations. The broad-spectrum activity achieved by host targeting can be especially useful in combating emerging viruses and for treatment of diseases caused by multiple viral pathogens, such as opportunistic agents in immunosuppressed patients. We have developed a family of compounds that modulate sirtuin 2, an NAD+-dependent deacylase, and now report the properties of a member of that family, FLS-359. Biochemical and x-ray structural studies show that the drug binds to sirtuin 2 and allosterically inhibits its deacetylase activity. FLS-359 inhibits the growth of RNA and DNA viruses, including members of the coronavirus, orthomyxovirus, flavivirus, hepadnavirus, and herpesvirus families. FLS-359 acts at …
Authors
Kathryn L Roche,Stacy Remiszewski,Matthew J Todd,John L Kulp III,Liudi Tang,Alison V Welsh,Ashley P Barry,Chandrav De,William W Reiley,Angela Wahl,J Victor Garcia,Micah A Luftig,Thomas Shenk,James R Tonra,Eain A Murphy,Lillian W Chiang
Journal
Journal of Clinical Investigation
Published Date
2023/6/15
Virology under the microscope—a call for rational discourse
Viruses have brought humanity many challenges: respiratory infection, cancer, neurological impairment and immunosuppression to name a few. Virology research over the last 60+ years has responded to reduce this disease burden with vaccines and antivirals. Despite this long history, the COVID-19 pandemic has brought unprecedented attention to the field of virology. Some of this attention is focused on concern about the safe conduct of research with human pathogens. A small but vocal group of individuals has seized upon these concerns – conflating legitimate questions about safely conducting virus-related research with uncertainties over the origins of SARS-CoV-2. The result has fueled public confusion and, in many instances, ill-informed condemnation of virology. With this article, we seek to promote a return to rational discourse. We explain the use of gain-of-function approaches in science, discuss the …
Authors
Felicia Goodrum,Anice C Lowen,Seema Lakdawala,James Alwine,Arturo Casadevall,Michael J Imperiale,Walter Atwood,Daphne Avgousti,Joel Baines,Bruce Banfield,Lawrence Banks,Sumita Bhaduri-McIntosh,Deepta Bhattacharya,Daniel Blanco-Melo,David Bloom,Adrianus Boon,Steeve Boulant,Curtis Brandt,Andrew Broadbent,Christopher Brooke,Craig Cameron,Samuel Campos,Patrizia Caposio,Gary Chan,Anna Cliffe,John Coffin,Kathleen Collins,Blossom Damania,Matthew Daugherty,Kari Debbink,James DeCaprio,Terence Dermody,Jimmy Dikeakos,Daniel DiMaio,Rhoel Dinglasan,W Paul Duprex,Rebecca Dutch,Nels Elde,Michael Emerman,Lynn Enquist,Bentley Fane,Ana Fernandez-Sesma,Michelle Flenniken,Lori Frappier,Matthew Frieman,Klaus Frueh,Michaela Gack,Marta Gaglia,Tom Gallagher,Denise Galloway,Adolfo García-Sastre,Adam Geballe,Britt Glaunsinger,Stephen Goff,Alexander Greninger,Meaghan Hancock,Eva Harris,Nicholas Heaton,Mark Heise,Ekaterina Heldwein,Brenda Hogue,Stacy Horner,Edward Hutchinson,Joseph Hyser,William Jackson,Robert Kalejta,Jeremy Kamil,Stephanie Karst,Frank Kirchhoff,David Knipe,Timothy Kowalik,Michael Lagunoff,Laimonis Laimins,Ryan Langlois,Adam Lauring,Benhur Lee,David Leib,Shan-Lu Liu,Richard Longnecker,Carolina Lopez,Micah Luftig,Jennifer Lund,Balaji Manicassamy,Grant McFadden,Michael McIntosh,Andrew Mehle,W Allen Miller,Ian Mohr,Cary Moody,Nathaniel Moorman,Anne Moscona,Bryan Mounce,Joshua Munger,Karl Münger,Eain Murphy,Mojgan Naghavi,Jay Nelson,Christopher Neufeldt,Janko Nikolich,Christine O'Connor,Akira Ono,Walter Orenstein,David Ornelles,Jing-hsiung Ou,John Parker,Colin Parrish,Andrew Pekosz,Philip Pellett,Julie Pfeiffer,Richard Plemper,Stephen Polyak,John Purdy,Dohun Pyeon,Miguel Quinones-Mateu,Rolf Renne,Charles Rice,John Schoggins,Richard Roller,Charles Russell,Rozanne Sandri-Goldin,Martin Sapp,Luis Schang,Scott Schmid,Stacey Schultz-Cherry,Bert Semler,Thomas Shenk,Guido Silvestri,Viviana Simon,Gregory Smith,Jason Smith,Katherine Spindler,Megan Stanifer,Kanta Subbarao,Wesley Sundquist,Mehul Suthar,Troy Sutton,Andrew Tai,Vera Tarakanova,Benjamin TenOever,Scott Tibbetts,Stephen Tompkins,Zsolt Toth,Koenraad van Doorslaer,Marco Vignuzzi,Nicholas Wallace,Derek Walsh,Michael Weekes,Jason Weinberg,Matthew Weitzman,Sandra Weller
Journal
Journal of virology
Published Date
2023/2/28
Compositions and Methods for Inhibiting Cancers and Viruses
The present invention relates to compositions comprising isolated, single stranded RNA molecules and pharmaceutically acceptable carriers suitable for injection. The present invention relates to methods for stimulating an immune response and treating tumors. The present invention further relates to kits comprising a cancer vaccine and compositions of the present invention for use as an adjuvant to cancer vaccines.
Published Date
2022/6/30
Method to Produce Virus in Cultured Cells Supplemented With Alpha-Ketoglutarate
A method is provided to improve virus production is an infected host cell by culturing the infected cell in an effective amount of alpha-ketoglutarate.
Published Date
2021/12/9
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
Published Date
2021/9/28
Professor FAQs
What is Thomas Shenk's h-index at Princeton University?
The h-index of Thomas Shenk has been 45 since 2020 and 127 in total.
What are Thomas Shenk's top articles?
The articles with the titles of
An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity
Paul Berg: Recombinant DNA trailblazer
Sirtuin 4 (SIRT4) lipoamidase activity and uses thereof
An allosteric inhibitor of sirtuin 2 deacetylase activity exhibits broad-spectrum antiviral activity
Virology under the microscope—a call for rational discourse
Compositions and Methods for Inhibiting Cancers and Viruses
Method to Produce Virus in Cultured Cells Supplemented With Alpha-Ketoglutarate
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
...
are the top articles of Thomas Shenk at Princeton University.
What are Thomas Shenk's research interests?
The research interests of Thomas Shenk are: Biological sciences, biomedical sciences, virology
What is Thomas Shenk's total number of citations?
Thomas Shenk has 54,274 citations in total.
What are the co-authors of Thomas Shenk?
The co-authors of Thomas Shenk are Arturo Casadevall, James L. Manley, L. W. Enquist, Charles Samuel, Etienne Sibille, Todd Greco.